Trademark: 88462494
Status Date
Monday, December 14, 2020
Filing Date
Thursday, June 6, 2019
Published for Opposition
Tuesday, March 17, 2020
Abandoned Date
Monday, December 14, 2020
9 Downloadable computer software for drug discovery; downloadable computer software for the purpose of enabling automated molecular design; downloadable computer software for automated molecular design; downloadable computer software for design of molecules and synthetic chemicals using a biomolecular algorithm; downloadable computer software for biomolecule simulation in connection with drug and chemical design; downloadable computer software utilizing artificial intelligence and machine learning for biomolecule simulation and synthetic chemistry; downloadable computer software for validating novel disease-related targets; downloadable computer software incorporating artificial intelligence and quantum computing functions to automate drug and chemical discovery and development; downloadable computer software incorporating artificial intelligence and quantum computing functions to automate synthetic chemical discovery and development; downloadable computer software for computational automation of synthetic chemicals; downloadable computer software incorporating machine learning algorithms, models, and solutions for applications in pharmacology, biopharmaceuticals, energy, and optoelectronics; downloadable computer software for manipulating molecules; downloadable computer software for use in connection with pharmaceutical research and development in the fields of oncology, immunology, cardiology, pulmonology, CNS, psychiatry, dermatology, and endocrinology; downloadable computer software for pharmaceutical research and development in connection with infectious diseases, diabetes, metabolic diseases, internal diseases, and respiratory diseases
42 Providing temporary use of non-downloadable cloud-based computer software for drug discovery; providing temporary use of non-downloadable cloud-based computer software for the purpose of enabling automated molecular design; providing temporary use of non-downloadable cloud-based computer software for automated molecular design; providing an online, non-downloadable computer software platform for design of molecules and synthetic chemicals using a biomolecular algorithm; providing an online, non-downloadable computer software platform for biomolecule simulation in connection with drug and chemical design; providing an online, non-downloadable computer software platform utilizing artificial intelligence and machine learning for biomolecule simulation and synthetic chemistry; providing an online, non-downloadable computer software platform for validating novel disease-related targets; providing temporary use of non-downloadable cloud-based computer software incorporating artificial intelligence and quantum computing functions to automate drug and chemical discovery and development; providing temporary use of non-downloadable cloud-based computer software incorporating artificial intelligence and quantum computing functions to automate synthetic chemical discovery and development; providing temporary use of non-downloadable cloud-based computer software for computational automation of synthetic chemicals; providing temporary use of non-downloadable cloud-based computer software incorporating machine learning algorithms, models, and solutions for applications in pharmacology, biopharmaceuticals, energy, and optoelectronics; providing temporary use of non-downloadable cloud-based computer software for manipulating molecules; providing temporary use of non-downloadable cloud-based computer software for use in connection with pharmaceutical research and development in the fields of oncology, immunology, cardiology, pulmonology, CNS, psychiatry, dermatology, and endocrinology; providing temporary use of non-downloadable cloud-based computer software for pharmaceutical research and development in connection with infectious diseases, diabetes, metabolic diseases, internal diseases, and respiratory diseases
Dec 14, 2020
Abandonment Notice E-Mailed - No Use Statement Filed
Dec 14, 2020
Abandonment - No Use Statement Filed
Sep 14, 2020
Withdrawal Of Attorney Granted
Sep 14, 2020
Teas Withdrawal Of Attorney Received
Sep 10, 2020
Applicant/Correspondence Changes (Non-Responsive) Entered
Sep 10, 2020
Teas Change Of Correspondence Received
Sep 10, 2020
Teas Change Of Owner Address Received
May 12, 2020
Noa E-Mailed - Sou Required From Applicant
Mar 17, 2020
Official Gazette Publication Confirmation E-Mailed
Mar 17, 2020
Published For Opposition
Feb 26, 2020
Notification Of Notice Of Publication E-Mailed
Feb 11, 2020
Assigned To Lie
Feb 7, 2020
Approved For Pub - Principal Register
Feb 6, 2020
Teas/Email Correspondence Entered
Feb 5, 2020
Correspondence Received In Law Office
Feb 5, 2020
Teas Response To Office Action Received
Sep 3, 2019
Notification Of Non-Final Action E-Mailed
Sep 3, 2019
Non-Final Action E-Mailed
Sep 3, 2019
Non-Final Action Written
Aug 28, 2019
Assigned To Examiner
Jun 20, 2019
New Application Office Supplied Data Entered In Tram
Jun 10, 2019
New Application Entered In Tram
Trademark Alertz updated from USPTO on 2030-01-24
